1-8 of 8
Jean Viallet
Close
Sort by
Journal Articles

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

Clinical Trials & Observations
Susan M. O'Brien, David F. Claxton, Michael Crump, Stefan Faderl, Thomas Kipps, Michael J. Keating, Jean Viallet, Bruce D. Cheson
Journal: Blood
Blood (2009) 113 (2): 299–305.
https://doi.org/10.1182/blood-2008-02-137943
Published: 2009
Journal Articles

The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways.

Yue Wei, PhD, Tapan Kadia, MD, Weigang Tong, MD, PhD, Susan O’Brien, MD, Jean Viallet, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2008) 112 (11): 1633.
https://doi.org/10.1182/blood.V112.11.1633.1633
Published: 2008
Journal Articles

A Phase II Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by a 24-h Continuous Infusion Every 2 Weeks to Patients with Chronic Idiopathic Myelofibrosis (CIMF).

Srdan Verstovsek, MD, Azra Raza, MD, Aaron D. Schimmer, MD, Jean Viallet, MD, Hagop Kantarjian, MD
Journal: Blood
Blood (2007) 110 (11): 3553.
https://doi.org/10.1182/blood.V110.11.3553.3553
Published: 2007
Journal Articles

Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.

Shaozhong Dong, PhD, Sumin Kang, PhD, Sagar Lonial, MD, Hanna Jean Khoury, MD, Jean Viallet, PhD, Jing Chen, PhD
Journal: Blood
Blood (2007) 110 (11): 2920.
https://doi.org/10.1182/blood.V110.11.2920.2920
Published: 2007
Journal Articles

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies.

Aaron D. Schimmer, MD, Joseph Brandwein, MD, Susan M. O’Brien, MD, Hagop Kantarjian, MD, Bruce D. Cheson, MD, Mark D. Minden, MD, Karen Yee, MD, Andre Schuh, MD, Vikas Gupta, MD, Jean Viallet, MD, Gautam Borthakur, MD
Journal: Blood
Blood (2007) 110 (11): 892.
https://doi.org/10.1182/blood.V110.11.892.892
Published: 2007
Journal Articles

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by 24 Hour Infusion Every 2 Weeks to Patients with Myeloid Malignancies and Chronic Lymphocytic Leukemia (CLL).

Gautam Borthakur, Susan O’Brien, Farhad Ravandi-Kashani, Francis Giles, Aaron D. Schimmer, Jean Viallet, Hagop Kantarjian
Journal: Blood
Blood (2006) 108 (11): 2654.
https://doi.org/10.1182/blood.V108.11.2654.2654
Published: 2006
Journal Articles

Inhibition of Bcl-2 Signaling by Small Molecule BH3 Inhhibitor GX15-070 as a Novel Therapeutic Strategy in AML.

Julie C. Watt, Marina Konopleva, M.D., Ph.D., Rooha Contractor, Ismael Samudio, Ph.D., David Harris, Zeev Estrov, M.D., Jean Viallet, M.D., Michael Andreeff, M.D., Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2584.
https://doi.org/10.1182/blood.V108.11.2584.2584
Published: 2006
Journal Articles

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).

Susan O’Brien, MD, Thomas J. Kipps, MD, Stefan Faderl, MD, Michael Crump, MD, Michael J. Keating, MD, Blanche Anderson, Claudia Soho, Jan Bole, Ruth Turner, Jean Viallet, MD, Bruce D. Cheson, MD
Journal: Blood
Blood (2005) 106 (11): 446.
https://doi.org/10.1182/blood.V106.11.446.446
Published: 2005